São Paulo, Brazil and Fairfield, New Jersey November, 2022 – Eurofarma, a multinational pharmaceutical company based in Brazil, and one of the largest pharmaceutical companies in Latin America, announced its entry into the U.S. market with the acquisition of Medimetriks Pharmaceuticals, Inc.  This strategic acquisition in the United States furthers Eurofarma’s goal to build a global pharmaceutical company.

Founded in 2008, Medimetriks is a leading dermatology company that develops, acquires and commercializes prescription skin care brands. The Company’s portfolio includes brands indicated for acne, rosacea, psoriasis, fungal infections and dystrophic nails. Medimetriks is well known for its commercial strength anchored by its dedicated national sales force and robust development activities.

This is Eurofarma's first acquisition outside of Latin America and comes just weeks after the Company was inspected by the U.S. Food and Drug Administration (FDA), the agency that regulates drugs in the United States.  FDA provided Eurofarma with Voluntary Action Indicated (VAI) classification, which indicates that the Company meets the manufacturing standards required by FDA for current good manufacturing practices (CGMPs) and potential future product approvals for the U.S. market. 

Maria Del Pilar Muñoz, Vice President of Sustainability and New Business at Eurofarma, says “our internationalization began in 2009 and, after just over a decade, we now operate in all 20 Latin American countries. Entering the U.S. market on the year of our 50th anniversary is especially significant as it underscores our commitment to build a global pharmaceutical company. Medimetriks is a well-respected, focused operation with high growth potential, and will serve as a platform for new investments in the U.S.” 

Alexandre de Godoy Moreira Graziotto, Eurofarma's Corporate Strategy and Business Development Director, says “this acquisition is a great achievement that gives us access to the largest pharmaceutical market in the world.  The VAI classification by FDA allows us to expand our future production for the U.S. market and other countries, boosting our capacity to grow by exporting products and serving international markets.”

Bradley Glassman, President and CEO of Medimetriks, said “together with Eurofarma, Medimetriks will more aggressively expand its operations by acquiring new products and developing its pipeline.  We remain committed to investing in the future of the Dermatology and Podiatry specialties we serve and, with Eurofarma, we are excited to further deliver on our mission to meet the unmet needs of Dermatology and Podiatry patients. 

The transaction has already been completed and is effective immediately.

About Eurofarma Group

The Eurofarma Group has been operating in the healthcare industry for 50 years, producing and marketing innovative products and services to improve people’s quality of life. With diversified operations, the company operates in all major segments, such as Prescription, Non-Prescription, Generic, Hospital, and Oncology. In Brazil alone, it offers more than 430 products, serves all medical specialties, and covers upwards of 200 therapeutic classes, accounting for 80% of the total market.

The Eurofarma Group is present in more than 20 countries, with 10 manufacturing plants in Latin America. Reported net sales totaled BRL 7 billion in 2021 and the Group employs over 8,800 people.

Eurofarma on social media

Facebook: @eurofarma | LinkedIn: @eurofarma

Instagram: @eurofarma | Youtube: @eurofarmalab

Eurofarma Press Information

G&A Public Relations 

Carolina Carone – +55 11 98578-1604 – carolina.carone@gaspar.com.br 

Guilherme Gaspar – +55 11 98285-6000 – guilherme@gaspar.com.br

Medimetriks Press Information

David Addis – +1 973 882 7512 ext. 569 – daddis@medimetriks.com